ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 66 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $804,506 | -33.3% | 1,031,417 | -21.0% | 0.00% | – |
| Q2 2023 | $1,207,045 | -15.1% | 1,304,914 | +0.1% | 0.00% | – |
| Q1 2023 | $1,421,000 | +97095.6% | 1,303,843 | +30.2% | 0.00% | – |
| Q4 2022 | $1,462 | -99.9% | 1,001,112 | -0.6% | 0.00% | – |
| Q3 2022 | $1,083,000 | -56.8% | 1,006,832 | -31.7% | 0.00% | – |
| Q2 2022 | $2,506,000 | -13.1% | 1,474,163 | +5.3% | 0.00% | – |
| Q1 2022 | $2,884,000 | -48.0% | 1,399,765 | -5.3% | 0.00% | -100.0% |
| Q4 2021 | $5,542,000 | -32.8% | 1,478,038 | -7.4% | 0.00% | 0.0% |
| Q3 2021 | $8,253,000 | +4.4% | 1,596,261 | -14.0% | 0.00% | 0.0% |
| Q2 2021 | $7,908,000 | -11.7% | 1,856,323 | +10.1% | 0.00% | 0.0% |
| Q1 2021 | $8,951,000 | +61.4% | 1,685,720 | +63.9% | 0.00% | 0.0% |
| Q4 2020 | $5,545,000 | +54.6% | 1,028,803 | +119.7% | 0.00% | 0.0% |
| Q3 2020 | $3,587,000 | -28.4% | 468,313 | -6.4% | 0.00% | 0.0% |
| Q2 2020 | $5,007,000 | +1796.6% | 500,231 | +417.1% | 0.00% | – |
| Q1 2020 | $264,000 | +190.1% | 96,737 | +26.9% | 0.00% | – |
| Q4 2019 | $91,000 | -81.0% | 76,206 | -75.9% | 0.00% | – |
| Q3 2019 | $478,000 | -56.9% | 316,829 | +13.9% | 0.00% | – |
| Q2 2019 | $1,110,000 | -35.8% | 278,120 | -30.9% | 0.00% | – |
| Q1 2019 | $1,730,000 | -31.0% | 402,354 | -7.8% | 0.00% | -100.0% |
| Q4 2018 | $2,509,000 | +24.6% | 436,278 | +193.7% | 0.00% | – |
| Q3 2018 | $2,014,000 | -20.0% | 148,525 | -29.9% | 0.00% | -100.0% |
| Q2 2018 | $2,516,000 | +20.7% | 211,990 | +14.2% | 0.00% | – |
| Q1 2018 | $2,085,000 | +1389.3% | 185,660 | +786.0% | 0.00% | – |
| Q4 2017 | $140,000 | +79.5% | 20,956 | +118.2% | 0.00% | – |
| Q3 2017 | $78,000 | +188.9% | 9,604 | +57.7% | 0.00% | – |
| Q2 2017 | $27,000 | -76.1% | 6,090 | -70.4% | 0.00% | – |
| Q1 2017 | $113,000 | -17.5% | 20,590 | -39.2% | 0.00% | – |
| Q4 2016 | $137,000 | -8.1% | 33,843 | +60.5% | 0.00% | – |
| Q3 2016 | $149,000 | – | 21,087 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 6,287,101 | $4,903,939 | 2.63% |
| Syncona Portfolio Ltd | 1,377,294 | $1,074,289 | 1.60% |
| MPM BioImpact LLC | 5,095,912 | $3,974,811 | 1.06% |
| NEA Management Company, LLC | 17,079,778 | $13,322,227 | 1.03% |
| TANG CAPITAL MANAGEMENT LLC | 5,166,954 | $4,030,224 | 0.57% |
| PFM Health Sciences, LP | 10,423,135 | $8,130,045 | 0.38% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,399,864 | 0.36% |
| Long Focus Capital Management, LLC | 10,963,158 | $8,551,263 | 0.31% |
| Acuitas Investments, LLC | 479,764 | $374,216 | 0.22% |
| Endurant Capital Management LP | 311,944 | $243,316 | 0.22% |